Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia

Richard J. Powell, Anthony J. Comerota, Scott A. Berceli, Raul Guzman, Timothy D. Henry, Edith Tzeng, Omaida C Velazquez, William A. Marston, Ronnda L. Bartel, Amy Longcore, Theresa Stern, Sharon Watling

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Objectives: Cell therapy is a novel experimental treatment modality for patients with critical limb ischemia (CLI) of the lower extremities and no other established treatment options. This study was conducted to assess the safety and clinical efficacy of intramuscular injection of autologous tissue repair cells (TRCs). Methods: A prospective, randomized double-blinded, placebo controlled, multicenter study (RESTORE-CLI) was conducted at 18 centers in the United States in patients with CLI and no option for revascularization. Enrollment of 86 patients began in April 2007 and ended in February 2010. For the prospectively planned interim analysis, conducted in February 2010, 33 patients had the opportunity to complete the trial (12 months of follow-up), and 46 patients had completed at least 6 months of follow-up. The interim analysis included analysis of both patient populations. An independent physician performed the bone marrow or sham control aspiration. The aspirate was processed in a closed, automated cell manufacturing system for approximately 12 days to generate the TRC population of stem and progenitor cells. An average of 136 ± 41 × 10 6 total viable cells or electrolyte (control) solution were injected into 20 sites in the ischemic lower extremity. The primary end point was safety as evaluated by adverse events, and serious adverse events as assessed at multiple follow-up time points. Clinical efficacy end points included major amputation-free survival and time to first occurrence of treatment failure (defined as any of the following: major amputation, death, de novo gangrene, or doubling of wound size), as well as major amputation rate and measures of wound healing. Results: There was no difference in adverse or serious adverse events between the two groups. Statistical analysis revealed a significant increase in time to treatment failure (log-rank test, P =.0053) and amputation-free survival in patients receiving TRC treatment, (log-rank test, P =.038). Major amputation occurred in 19% of TRC-treated patients compared to 43% of controls (P =.14, Fisher exact test). There was evidence of improved wound healing in the TRC-treated patients when compared with controls at 12 months. Conclusions: Intramuscular injection of autologous bone marrow-derived TRCs is safe and decreases the occurrence of clinical events associated with disease progression when compared to placebo in patients with lower extremity CLI and no revascularization options.

Original languageEnglish
Pages (from-to)1032-1041
Number of pages10
JournalJournal of Vascular Surgery
Volume54
Issue number4
DOIs
StatePublished - Oct 1 2011

Fingerprint

Ischemia
Extremities
Bone Marrow
Placebos
Amputation
Lower Extremity
Intramuscular Injections
Treatment Failure
Wound Healing
Stem Cells
Safety
Gangrene
Survival
Cell- and Tissue-Based Therapy
Electrolytes
Population
Multicenter Studies
Disease Progression
Therapeutics
Physicians

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. / Powell, Richard J.; Comerota, Anthony J.; Berceli, Scott A.; Guzman, Raul; Henry, Timothy D.; Tzeng, Edith; Velazquez, Omaida C; Marston, William A.; Bartel, Ronnda L.; Longcore, Amy; Stern, Theresa; Watling, Sharon.

In: Journal of Vascular Surgery, Vol. 54, No. 4, 01.10.2011, p. 1032-1041.

Research output: Contribution to journalArticle

Powell, Richard J. ; Comerota, Anthony J. ; Berceli, Scott A. ; Guzman, Raul ; Henry, Timothy D. ; Tzeng, Edith ; Velazquez, Omaida C ; Marston, William A. ; Bartel, Ronnda L. ; Longcore, Amy ; Stern, Theresa ; Watling, Sharon. / Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. In: Journal of Vascular Surgery. 2011 ; Vol. 54, No. 4. pp. 1032-1041.
@article{db33bbf8f490424ba18eae24addc1aba,
title = "Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia",
abstract = "Objectives: Cell therapy is a novel experimental treatment modality for patients with critical limb ischemia (CLI) of the lower extremities and no other established treatment options. This study was conducted to assess the safety and clinical efficacy of intramuscular injection of autologous tissue repair cells (TRCs). Methods: A prospective, randomized double-blinded, placebo controlled, multicenter study (RESTORE-CLI) was conducted at 18 centers in the United States in patients with CLI and no option for revascularization. Enrollment of 86 patients began in April 2007 and ended in February 2010. For the prospectively planned interim analysis, conducted in February 2010, 33 patients had the opportunity to complete the trial (12 months of follow-up), and 46 patients had completed at least 6 months of follow-up. The interim analysis included analysis of both patient populations. An independent physician performed the bone marrow or sham control aspiration. The aspirate was processed in a closed, automated cell manufacturing system for approximately 12 days to generate the TRC population of stem and progenitor cells. An average of 136 ± 41 × 10 6 total viable cells or electrolyte (control) solution were injected into 20 sites in the ischemic lower extremity. The primary end point was safety as evaluated by adverse events, and serious adverse events as assessed at multiple follow-up time points. Clinical efficacy end points included major amputation-free survival and time to first occurrence of treatment failure (defined as any of the following: major amputation, death, de novo gangrene, or doubling of wound size), as well as major amputation rate and measures of wound healing. Results: There was no difference in adverse or serious adverse events between the two groups. Statistical analysis revealed a significant increase in time to treatment failure (log-rank test, P =.0053) and amputation-free survival in patients receiving TRC treatment, (log-rank test, P =.038). Major amputation occurred in 19{\%} of TRC-treated patients compared to 43{\%} of controls (P =.14, Fisher exact test). There was evidence of improved wound healing in the TRC-treated patients when compared with controls at 12 months. Conclusions: Intramuscular injection of autologous bone marrow-derived TRCs is safe and decreases the occurrence of clinical events associated with disease progression when compared to placebo in patients with lower extremity CLI and no revascularization options.",
author = "Powell, {Richard J.} and Comerota, {Anthony J.} and Berceli, {Scott A.} and Raul Guzman and Henry, {Timothy D.} and Edith Tzeng and Velazquez, {Omaida C} and Marston, {William A.} and Bartel, {Ronnda L.} and Amy Longcore and Theresa Stern and Sharon Watling",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.jvs.2011.04.006",
language = "English",
volume = "54",
pages = "1032--1041",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia

AU - Powell, Richard J.

AU - Comerota, Anthony J.

AU - Berceli, Scott A.

AU - Guzman, Raul

AU - Henry, Timothy D.

AU - Tzeng, Edith

AU - Velazquez, Omaida C

AU - Marston, William A.

AU - Bartel, Ronnda L.

AU - Longcore, Amy

AU - Stern, Theresa

AU - Watling, Sharon

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Objectives: Cell therapy is a novel experimental treatment modality for patients with critical limb ischemia (CLI) of the lower extremities and no other established treatment options. This study was conducted to assess the safety and clinical efficacy of intramuscular injection of autologous tissue repair cells (TRCs). Methods: A prospective, randomized double-blinded, placebo controlled, multicenter study (RESTORE-CLI) was conducted at 18 centers in the United States in patients with CLI and no option for revascularization. Enrollment of 86 patients began in April 2007 and ended in February 2010. For the prospectively planned interim analysis, conducted in February 2010, 33 patients had the opportunity to complete the trial (12 months of follow-up), and 46 patients had completed at least 6 months of follow-up. The interim analysis included analysis of both patient populations. An independent physician performed the bone marrow or sham control aspiration. The aspirate was processed in a closed, automated cell manufacturing system for approximately 12 days to generate the TRC population of stem and progenitor cells. An average of 136 ± 41 × 10 6 total viable cells or electrolyte (control) solution were injected into 20 sites in the ischemic lower extremity. The primary end point was safety as evaluated by adverse events, and serious adverse events as assessed at multiple follow-up time points. Clinical efficacy end points included major amputation-free survival and time to first occurrence of treatment failure (defined as any of the following: major amputation, death, de novo gangrene, or doubling of wound size), as well as major amputation rate and measures of wound healing. Results: There was no difference in adverse or serious adverse events between the two groups. Statistical analysis revealed a significant increase in time to treatment failure (log-rank test, P =.0053) and amputation-free survival in patients receiving TRC treatment, (log-rank test, P =.038). Major amputation occurred in 19% of TRC-treated patients compared to 43% of controls (P =.14, Fisher exact test). There was evidence of improved wound healing in the TRC-treated patients when compared with controls at 12 months. Conclusions: Intramuscular injection of autologous bone marrow-derived TRCs is safe and decreases the occurrence of clinical events associated with disease progression when compared to placebo in patients with lower extremity CLI and no revascularization options.

AB - Objectives: Cell therapy is a novel experimental treatment modality for patients with critical limb ischemia (CLI) of the lower extremities and no other established treatment options. This study was conducted to assess the safety and clinical efficacy of intramuscular injection of autologous tissue repair cells (TRCs). Methods: A prospective, randomized double-blinded, placebo controlled, multicenter study (RESTORE-CLI) was conducted at 18 centers in the United States in patients with CLI and no option for revascularization. Enrollment of 86 patients began in April 2007 and ended in February 2010. For the prospectively planned interim analysis, conducted in February 2010, 33 patients had the opportunity to complete the trial (12 months of follow-up), and 46 patients had completed at least 6 months of follow-up. The interim analysis included analysis of both patient populations. An independent physician performed the bone marrow or sham control aspiration. The aspirate was processed in a closed, automated cell manufacturing system for approximately 12 days to generate the TRC population of stem and progenitor cells. An average of 136 ± 41 × 10 6 total viable cells or electrolyte (control) solution were injected into 20 sites in the ischemic lower extremity. The primary end point was safety as evaluated by adverse events, and serious adverse events as assessed at multiple follow-up time points. Clinical efficacy end points included major amputation-free survival and time to first occurrence of treatment failure (defined as any of the following: major amputation, death, de novo gangrene, or doubling of wound size), as well as major amputation rate and measures of wound healing. Results: There was no difference in adverse or serious adverse events between the two groups. Statistical analysis revealed a significant increase in time to treatment failure (log-rank test, P =.0053) and amputation-free survival in patients receiving TRC treatment, (log-rank test, P =.038). Major amputation occurred in 19% of TRC-treated patients compared to 43% of controls (P =.14, Fisher exact test). There was evidence of improved wound healing in the TRC-treated patients when compared with controls at 12 months. Conclusions: Intramuscular injection of autologous bone marrow-derived TRCs is safe and decreases the occurrence of clinical events associated with disease progression when compared to placebo in patients with lower extremity CLI and no revascularization options.

UR - http://www.scopus.com/inward/record.url?scp=80053650560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053650560&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2011.04.006

DO - 10.1016/j.jvs.2011.04.006

M3 - Article

C2 - 21684715

AN - SCOPUS:80053650560

VL - 54

SP - 1032

EP - 1041

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 4

ER -